No Data
Jiangsu Kanion Pharmaceutical (600557.SH): Received the clinical trial approval notice for Lianchan Gengnian Granules.
On March 27, Gelonghui reported that Jiangsu Kanion Pharmaceutical (600557.SH) announced that it recently received the "Notice of Approval for Clinical Trials of Pharmaceuticals" issued by the National Medical Products Administration for Lianshen Menopausal Granules. The prescription for Lianshen Menopausal Granules is derived from clinical experience, with the functions of nourishing yin and clearing heat, calming the mind, and relieving anxiety. It is used for menopausal syndrome (with symptoms of yin deficiency and excess heat), manifesting as hot flashes, sweating, irritability, insomnia with vivid dreams, palpitations, anxiety and agitation, dizziness, and tinnitus.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Kanion Pharma to Trial Guben Xiaozhan Granules
Kanion Pharma's Unit to Trial Vascular Dementia Drug
Jiangsu Kanion Pharmaceutical (600557.SH): The new clinical trial for the indication of vascular dementia for epimedium flavonoid capsules has been approved.
Jiangsu Kanion Pharmaceutical (600557.SH) announced that its holding subsidiary Jiangsu Kanion Sunshine Pharmaceutical Co., Ltd. (“...
Jiangsu Kanion Pharmaceutical (600557.SH): Received the clinical trial approval notification for the Gu Ben Xiao Zhen granules.
On March 4, Gelonghui reported that Jiangsu Kanion Pharmaceutical (600557.SH) announced it has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Gu Ben Xiao Zhen granules. The prescription for Gu Ben Xiao Zhen granules is derived from clinical experience. Its functions and indications are to invigorate Qi, warm Yang, dispel wind, and fortify the exterior. It is used for chronic spontaneous urticaria with a deficiency in stabilizing the exterior.
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough